

CURRICULUM VITAE

PERSONAL DETAILS

NAME Dr. Debranjani Chattopadhyay (M.B.B.S., M.D., D.M., Dr.N.B.)

GENDER Female

DATE OF BIRTH 14th AUGUST 1984

CURRENT POST Consultant

Department of Clinical Hematology and Cellular
Therapies, Tata Medical Center, Kolkata

CONTACT NUMBER 9092536203

EMAIL drdebranjani@gmail.com

debranjani.chattopadhyay@tmckolkata.com

MEDICAL REGISTRATION 85998 (Tamil Nadu Medical Council), February 2009

ACADEMIC CAREER

<i>Professional Education</i>	<i>Period</i>		<i>Institute</i>
	<i>From</i>	<i>To</i>	
Bachelor of Medicine & Bachelor of Surgery (M.B.B.S.) - <i>Graduation</i>	July 2003	December 2007	Jawaharlal Institute of Postgraduate Medical Education and Research,
<i>Internship</i>	December 2007	December 2008	J.I.P.M.E.R., Pondicherry
Doctor of Medicine (M.D) in General Medicine <i>Post-Graduation</i>	May 2011	May 2014	Madurai Medical College, Madurai, Tamil Nadu Dr.M.G.R Medical University, Tamil Nadu.
Doctorate of Medicine (D.M) in Clinical Hematology	July 2018	July 2021	All India Institute of Medical Sciences,
Doctorate of National Board (DrNB) in Clinical Hematology	Completed in March 2022		A.I.I.M.S., Rishikesh, Uttarakhand

Accolades:

- ❖ Awarded the **CERTIFICATE OF HONOUR** in PEDIATRICS year 2007
- ❖ Awarded the **CERTIFICATE OF HONOUR** in OBSTETRICS & GYNAECOLOGY, 2007
- ❖ **Distinction** in BIOCHEMISTRY, year 2004
- ❖ **Distinction** in MICROBIOLOGY, year 2005
- ❖ **Distinction** in PREVENTIVE AND SOCIAL MEDICINE year 2006
- ❖ **S.R.I. V. MANICASSAMY ENDOWMENT PRIZE AND GOLD MEDAL** in PREVENTIVE AND SOCIAL MEDICINE for 2006.
- ❖ Awarded **BEST PROJECT** for **MODULAR PROJECT** done on – Psychosocial and Therapeutic Aspects in a 12-year-old girl with epilepsy – for the year 2006
- ❖ **WINNER** in annual **TAMILNADU INTERCOLLEGIATE POSTGRADUATE HEMATOLOGY QUIZ 2013** held at GKNM HOSPITAL AND VALAVADI NARAYANASWAMY CANCER CENTRE, COIMBATORE.

Additional Courses / qualifications:

- Workshop on LYMPHOMA DIAGNOSIS and MANAGEMENT – by Dr.Sumeet Gujral, June 2019, A.I.I.M.S. Rishikesh
- Workshop on HAND HYGIENE AND BIOCHEMICAL WASTE MANAGEMENT, March 2019, A.I.I.M.S. Rishikesh
- Workshop on OCCUPATIONAL HAZARD AND VACCINATION, March 2019, A.I.I.M.S. Rishikesh
- Workshop on POINT OF CARE ULTRASOUND – P.O.C.U.S., May 2019, A.I.I.M.S. Rishikesh
- Workshop on BASIC AIRWAY MANAGEMENT, June 2019, A.I.I.M.S. Rishikesh
- Workshop on “N.A.T.: A Promise for Safer Transfusions, August 2019, A.I.I.M.S. Rishikesh
- N.H.M. Hemophilia Training Program Workshop, July 2019, A.I.I.M.S. Rishikesh
- American Heart Association BASIC LIFE SUPPORT (C.P.R. and AED) program, August 2019, A.I.I.M.S. Rishikesh

- American Heart Association ADVANCED CARDIOVASCULAR LIFE SUPPORT (ACLS) PROGRAM, August 2019, A.I.I.M.S. Rishikesh
- Workshop on Diagnosis of Hematological Disorders – Dr.Tejinder Singh, October 2019, A.I.I.M.S. Rishikesh.

CLINICAL EXPERIENCE:

<i>Post Held</i>	<i>Period</i>		<i>Institute</i>
	<i>From</i>	<i>To</i>	
Assistant Professor, General Medicine	June 2014	January 2015	Sri ManakulaVinayagar Medical College and Hospital, Pondicherry
General Physician	November 2015	February 2016	St. Joseph' Hospital (C.L.U.N.Y.) Pondicherry
Senior Resident Clinical Hematology	March 2015	May 2018	Christian Medical College, Vellore, Tamil Nādu
Assistant Professor, Department of Clinical Hematology	October 2021	April 2022	Christian Medical College, Vellore, Tamil Nādu
Clinical Associate Department of Clinical Hematology and Cellular Therapies	May 2022	December 2022	Tata Medical Center, Kolkata, West Bengal
Junior Consultant Department of Clinical Hematology and Cellular Therapies	December 2022	November 2023	Tata Medical Center, Kolkata, West Bengal
Associate Consultant Department of Clinical Hematology and Cellular Therapies	December 2023	Till Date	Tata Medical Center, Kolkata, West Bengal

RESEARCH:

- ❖ **M.D DISSERTATION:** A Study on Complete Hemogram and CD4 Count Correlation As A Prognostic Indicator In H.I.V. Patients.
- ❖ **D.M. THESIS:** Comparison of High Dose Dexamethasone and Prednisolone as The First-Line Treatment of Newly Diagnosed Immune Thrombocytopenia and Correlation with Regulatory T lymphocytes A Randomized Control Trial, Clinical Trial Registry of India (C.T.R.I.). Registration no. C.T.R.I./2019/08/020501

POSTERS PRESENTED:

1. Short term results with Hyper C.V.A.D. – M.A. protocol in Acute Lymphoblastic Leukemia/Lymphoma: A Single-Center Study from North India – HOPE ASIA KOLKATA August 2019 – E.H.A. Chapter
2. Outcomes of Treatment in Patients with Acute Myeloid Leukemia: A Single Centre experience from North India – HEMATOCON November 2019 – I.S.H.B.T. - Indian J Hematol Blood Transfus (2019) 35:S1–S151, <https://doi.org/10.1007/s12288-019-01207-5>
3. Core Binding Factor A.M.L. – Is It Good Risk!!! – Real World Data on Survival Outcomes from A Tertiary Care Center in Eastern India – HEMATOCON November 2019 – I.S.H.B.T. –Indian J Hematol Blood Transfus (Nov 2022) 38(Suppl 1):S1–S152, <https://doi.org/10.1007/s12288-022-01605-2>

PUBLICATIONS:

1. Bhagyanagar A, A. K B, K S, **Chattopadhyay D.** A Case Of Lithium Induced Nephrotoxicity In A 41-Year-Old Woman With Bipolar Disorder. jemds.2014 Oct 30;3(57):13034–9
2. Nath UK, **Chattopadhyay D**, Bakliwal A, Vaniyath S, Chetia R, Rajoreya AK. Encouraging Results with ALL IC-BFM 2009 Protocol Therapy in Pediatric Acute Lymphoblastic Leukemia/Lymphoma in Resource-Limited Setting: A Single-Center Study from India. Blood. 2019 Nov 13;134(Supplement_1):5118–5118.
3. Nath UK, Vaniyath S, Chetia R, **Chattopadhyay D.** PB2162 Incidence & Severity Of Bortezomib-Induced Peripheral Neuropathy With The Use Of Generic Bortezomib In Monoclonal Gammopathies: A Prospective Study From India. HemaSphere. 2019 Jun;3(S1):971.
4. Mehta V, Mohanty A, Meena S, Rahul JS, Uttam Kumar N, **Chattopadhyay D.** et al. Wickerhamomyces anomalous: A Rare Cause of Fungemia Causing Febrile Neutropenia in Acute Lymphoblastic Leukemia. Adnan M, editor. Case Reports in Infectious Diseases. 2020

Dec 29; 2020;1-4.

5. Basu G, Anthony ML, Bakliwal A, **Chattopadhyay D**, Joshi PP, Arora RK, et al. Primary anaplastic lymphoma kinase-negative anaplastic large cell lymphoma of cervical spine presenting with quadriplegia: A case report and literature review. *Surgical Neurology International*. 2020 Nov 6; 11:373.
6. Mangain G, Naithani M, Patra P, Mangain M, Morang S, Nayak J, **Chattopadhyay D** et al. Next-Generation Sequencing Highlights of Diffuse Large B-cell Lymphoma in a Tertiary Care Hospital in North India. *Cureus* [Internet]. 2022 Aug 21 [cited 2022 Oct 2]; Available from: <https://www.cureus.com/articles/109124-next-generation-sequencing-highlights-of-diffuse-large-b-cell-lymphoma-in-a-tertiary-care-hospital-in-north-india>.
7. Sundriyal D, Nath UK, Kumar P, Gupta S, Joseph D, Vaniyath S, **Chattopadhyay D** et al. Audit of In-Hospital Mortality from a Medical Oncology and Hemato-Oncology Center with the Emphasis on Best Supportive Care. *South Asian J Cancer*. 2022 Mar 22;s-0041-1739042.
8. **Chattopadhyay, D. et al.** Balancing the Bleeding Risk & Treatment Related Complications in Immune Thrombocytopenia - an Unmet Need: Real-World Data from India. *Blood* **140**, 11257–11258 (2022).
9. Bakliwal A, **Chattopadhyay D**, Nath UK *et al.* Comparison of Dexamethasone Versus Prednisolone Pre-phase in Induction Therapy of Pediatric Acute Lymphoblastic Leukemia: A Single-Center, Randomized Controlled Study from India. *Blood* **140**, 11857–11859 (2022).
10. Nath U.K., Bhattacharyya D, **Chattopadhyay D** et al. Visceral leishmaniasis masquerading as drug-induced pancytopenia in myasthenia gravis. *Drug Discoveries & Therapeutics* **15**, 48-50. 10.5582/ddt.2020.03101.
11. Bandyopadhyay A, Palepu S, Dhamija P, Nath U.K, Chetia R, Bakliwal A, Vaniyath S, **Chattopadhyay D** & Handu S. (2023). Safety and efficacy of Vitamin D 3 supplementation with Imatinib in Chronic Phase- Chronic Myeloid Leukaemia: An Exploratory Randomized Controlled Trial. *B.M.J. Open*. 13. e066361. 10.1136/bmjopen-2022-066361.
12. **Chattopadhyay D**, Puthalath A & Nath Uttam (2023). Steroid Toxicity in Immune Thrombocytopenia A Series of Unfortunate Events: A Case Report. *E.M.J. Hematology*. 60-68. 10.33590/emjhematol/10307003.
13. **Chattopadhyay D**, Hajra S, Chandra H & Nath, UK. (2024). A rare case of primary myelofibrosis with novel cytogenetic abnormality -deletion 4q25. *Indian Journal of Pathology and Microbiology*. 10.4103/ijpm.ijpm 365-23.
14. **Chattopadhyay Debranjani**, Abraham Aby & George, Biju. (2024). Successful Hematopoietic Stem Cell Transplantation in a Child with Thalassemia major and Moderate Haemophilia A. *Indian Journal of Hematology and Blood Transfusion*. 10.1007/s12288-024-01751-9.
15. Nag A, K1 B, Kumar J, et al. (April 26, 2025) Bioequivalent Etermovir Usage for Prophylaxis

- in Haploidentical Stem Cell Transplantation at High Risk of CMV Reactivation: A Report of Two Cases From India. *Cureus* 17(4): e83035. DOI 10.7759/cureus.83035 (PDF) *Bioequivalent Letermovir Usage for Prophylaxis in Haploidentical Stem Cell Transplantation at High Risk of CMV Reactivation: A Report of Two Cases From India.*
16. Chetia R, Palepu S, Dutta V, et al. Upfront Combined Hydroxyurea and Imatinib versus Imatinib Monotherapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Randomized Controlled Trial. *South Asian J Cancer* 2024;00(00):00–00
17. “Melphalan-associated encephalopathy following autologous stem cell transplant: a transplanters’ nightmare! | Blood Cell Therapy,” *Blood Cell Therapy | The official journal of APBMT*. Accessed: Jun. 18, 2025. [Online]. Available: <https://bct.apbmt.org/articles/bct-2023-025/>

Clinical Trials Participated :

Clinical Trials Participated	Clinical Phase of Trial (I-IV)	Role in Trial (e.g. Investigator, Sub-Investigator)	Year in which trial was conducted
A phase III, open-label, multicenter, randomized study evaluating the safety and efficacy of Polatuzumab Vedotin in combination with Rituximab plus Gemcitabine plus Oxaliplatin (R-GemOx) versus R-GemOx alone in patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma.	III	Co-Investigator	2022
A randomized, 2-arm, phase 3 study of elranatamab (pf-06863135) versus lenalidomide in patients with newly diagnosed multiple myeloma after undergoing autologous stem-cell transplantation.	III	Co-Investigator	2021
A Phase I, Randomized, Dose and Schedule Evaluation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Belantamab Mafodotin Administered in Combination with Standard of Care in Participants with Newly Diagnosed Multiple Myeloma (DREMM - 14)	I	Co-Investigator	2024
A Phase 2a study of HT-6184 in subjects with IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndrome (MDS) and Symptomatic Anemia	IIa	Co-Investigator	2023
Effect of Pomalidomide-Bortezomib-Dexamethasone induction on MRD status in patients with newly diagnosed Multiple Myeloma	II	Co-Investigator	2019
Chronic Myeloid Leukemia Database of Hematological Cancer Consortium: Hematological Cancers Registry	IV	Co-Investigator	2023

Acute Myeloid Leukemia Database of Hematological Cancer Consortium: Hematological Cancers Registry	IV	Co-Investigator	2023
A Double-Blind, Randomized Clinical Study of the Efficacy and Safety of Monotherapy with BCD-264 and Darzalex® in Subjects with Relapsed and Refractory Multiple Myeloma	III	Co-Investigator	2024
A Phase 1, Open Label, Dose Escalation, Multicenter, First-in-Human (FIH) Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR112 in Patients with Relapsed Advanced Lymphoma (ADITI-1).	I	Co-Investigator	2025
A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/μL).	III	Co-Investigator	2024
A Phase 1, Open Label, Dose Escalation, Dose Expansion, Multicenter Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR108 in Patients with Relapsed Advanced Lymphoma (ASHA-1).	I	Co-Investigator	2023
A Phase 1, Open Label, Dose Escalation, Dose Expansion, Multicenter, First in Human (FIH) Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR107 in Patients with Relapsed Advanced Malignancies (SHAKTI-1).	I	Co-Investigator	2025
A Phase 1/2, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of DRL-1801 in Patients with RRMM (SWASTH).	I/2	Co-Investigator	2025
A randomized, 2-arm, phase 3 study of elranatamab (pf-06863135) versus lenalidomide in patients with newly diagnosed multiple myeloma after undergoing autologous stem-cell transplantation (MAGNETISMM 7).	III	Co-Investigator	2025
An Open Label, Multicenter, Phase IV Study of Teclistamab to Evaluate its Safety in Indian Participants with Relapsed and Refractory Multiple Myeloma who have previously received at least 3 prior lines of therapy including an Immunomodulatory agent, a Proteasome Inhibitor and an Anti-CD38 antibody and have demonstrated disease progression on the last therapy.	IV	Co-Investigator	2025
A Double-Blind, Randomized clinical study of the efficacy and safety of monotherapy with BCD-264 and Darzalex® in subjects with Relapsed and Refractory Multiple Myeloma (DARVIVA).	III	Co-Investigator	2024

AREAS OF INTEREST:

1. Benign Hematology: Aplastic Anaemia / P.N.H./ Thalassemia- Transplant and Non-Transplant Management, Thrombocytopenia and Platelet Function Disorders
2. Malignant Hematology – Acute Leukemia and Lymphomas -- Chemotherapy and Autologous and Allogeneic Transplant,
3. Myeloproliferative Neoplasms and Myelodysplastic Syndromes.

PROFESSIONAL SUMMARY

- ❖ Clinical hematologist with specialization in Internal Medicine.
- ❖ Certified practitioner with 8 years experience in treating patients with Lymphoma, Leukemia, Myeloma, Hematopoietic Stem Cell transplant, Aplastic Anemias, Bone Marrow Failure Syndromes, Bleeding disorders and Thrombotic States.

~ 0 ~



30-MAR-2026



Hereby Certifies that
**DEBRANJANI
CHATTOPADHYAY**

has completed the e-learning course
**ICH GOOD CLINICAL
PRACTICE E6(R3)**

with a score of

100%

on

30/03/2026

This e-learning course has been formally recognised for its quality and content by
the following organisations and institutions



*This ICH E6 GCP Investigator Site Training meets the Minimum Criteria for ICH
GCP Investigator Site Personnel Training identified by TransCelerate BioPharma
as necessary to enable mutual recognition of GCP training among trial sponsors.*

Global Health Training Centre
globalhealthtrainingcentre.org/elearning

Certificate Number 8271801d-e81a-4cae-b18d-5f79f0b582f0 Version number 0



West Bengal Medical Council

IB - 196, Sector - III, Salt Lake, Kolkata - 700 106 * E-mail : wbmc@wbmc.in

Website : www.wbmc.wb.gov.in




Certificate of Registration

Certificate Number 99421

KOLKATA, THE 06 MAY, 20

Name	Guardian Name Father's/Mother's/ Husband's Name	Address or appointment	Date of Registration	Qualification and dates there
CHATTOPADHYAY DEBRANJANI	TAPAS CHATTOPADHYAY	VASUNDHARA APARTMENTS, 2ND FLOOR, 8, THILLAI NAADAR STREET KUUCHIKUPPAM, PONDICHERRY, P.O.-PUDUCHERRY, P.S.-PUDUCHERRY, DIST.-PUDUCHERRY, STATE-PUDUCHERRY, COUNTRY-INDIA, PIN-605001	06-05-2025	M B B S (PONDICHERRY UNIVERSITY), 2008
Date of Birth 14/08/1984				

It is hereby certified that this is a true Copy of the entries of the above specified Name in Columns 3, 5, 2, and 6 of the Register of Registered Practitioners.



Registrar
West Bengal Medical Council



IMPORTANT NOTICE

Every Registered Medical Practitioner should be careful to send to the Registrar immediate Notice of any change in his/her address, and also to answer all enquiries that may be sent to him/her by the Registrar in regard thereto, in order that his/her correct address may be duly inserted in the Register of Registered Practitioners, otherwise, by Section 16, Sub-section (2) of the Bengal Medical Act, 1914, such Practitioner is liable to have his/her name erased from the Register of Registered Practitioners.

Introduced w.e.f. 01.04.2017

TO BE RENEWED AFTER EVERY FIVE YEARS FROM THE DATE OF REGISTRATION